Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 641 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticancer agent Clear all
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 1 Interventional

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

NCT01273480
View directory record Official record
Conditions
Neoplasm Metastases
Interventions
Sequence 1, Sequence 2
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

NCT00252382
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
SNS-595 Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Scottsdale, Arizona • Louisville, Kentucky • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 1 Interventional

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

NCT03790488
View directory record Official record
Conditions
Cancer
Interventions
JTX-4014
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 7, 2026, 4:25 AM EST
Completed Not applicable Interventional Results available

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
antitumor drug screening assay, chemotherapy, biological therapy
Other · Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 2 Interventional

APX005M and Doxorubicin in Advanced Sarcoma

NCT03719430
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Doxorubicin, APX005M
Drug
Lead sponsor
Alexander Z. Wei, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 1 Interventional

Phase 1 Study of OTS167 in Patients With Solid Tumors

NCT01910545
View directory record Official record
Conditions
Solid Tumors, Metastatic Tumors
Interventions
OTS167IV
Drug
Lead sponsor
OncoTherapy Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 7, 2026, 4:25 AM EST
Withdrawn Phase 2 Interventional

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

NCT05212701
View directory record Official record
Conditions
Fatigue, Locally Advanced or Metastatic Breast Cancer
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cary, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Nov 7, 2026, 4:25 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Acapatamab, Enzalutamide, Abiraterone, AMG 404
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 2 Interventional

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

NCT00000801
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 1 Interventional

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02588105
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Nov 7, 2026, 4:25 AM EST
Suspended Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

NCT06620302
View directory record Official record
Conditions
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Interventions
Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
Biological · Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 39 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Commack, New York • Harrison, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 1 Interventional Results available

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

NCT02317016
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Nov 7, 2026, 4:25 AM EST
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
39
States / cities
Duarte, California • Glendale, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Terminated Phase 3 Interventional

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT01697072
View directory record Official record
Conditions
Gastric Cancer
Interventions
Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Nov 7, 2026, 4:25 AM EST
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Completed Phase 3 Interventional Results available

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

NCT02625623
View directory record Official record
Conditions
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Interventions
Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Nov 7, 2026, 4:25 AM EST
Completed No phase listed Observational

Acute Pain Caused by Paclitaxel in Patients With Cancer

NCT00860041
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pain questionnaires
Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
279
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 7, 2026, 4:25 AM EST
Not listed Phase 2 Interventional

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

NCT03544723
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Ad-p53
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Nov 7, 2026, 4:25 AM EST
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

NCT03983824
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Etoposide Phosphate, Mitoxantrone Hydrochloride, Multigated Acquisition Scan, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT06799065
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions
ATX-295, ATX-295 and bevacizumab (or biosimilar)
Drug
Lead sponsor
Accent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 7, 2026, 4:25 AM EST
Not listed Phase 1Phase 2 Interventional

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

NCT03787602
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
KRT-232, Avelumab
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Nov 7, 2026, 4:25 AM EST
Active, not recruiting Phase 2 Interventional Results available

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039
View directory record Official record
Conditions
Glioblastoma
Interventions
INCMGA00012, INCAGN01876, SRS, Brain surgery
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 7, 2026, 4:25 AM EST